- The company’s current osmolarity testing has been used over 24 million times,
with primary growth driven in cornea and premium cataract/refractive practices - Trukera Medical is positioned to expand its portfolio and address broader unmet
needs focused on advancing corneal health
SOUTHLAKE, Texas, Sept. 7, 2022 – TearLab® Corporation, the global leader in
ophthalmic point-of-care diagnostics, announced today that it will be expanding its
position in corneal health under the new name Trukera™ Medical. The rebranding
reflects the company’s vision and future growth strategy targeting a broader set of
unmet needs across corneal health.
“We continue to remain dedicated to the advancement of corneal health. Our decision
to rebrand as Trukera Medical represents our history as pioneers of point-of-care
testing for corneal disease, while also more clearly reflecting where we’re going next,”
said Trukera Medical CEO Adam Szaronos. “We expect to see strong continued growth
ahead with point-of-care diagnostics, driven primarily by practices specializing in cornea
and premium cataract/refractive surgery. This is where the physician and patient need is
greatest for advanced corneal health, and it’s where we find additional unmet needs
that we are positioned to address for our customers. Our vision is to be the world’s
leading and most trusted corneal health company for providers and patients, and the
leadership team and I are excited to introduce a name that represents this expanded
vision.”
TearLab introduced osmolarity testing as an innovative, objective diagnostic tool in the
eye care market with the TearLab Osmolarity System in 2010. The device has since
become a routine and even essential part of eye care, with over 24 million tests
completed worldwide. Doctors have come to rely on the objective clinical data from this
90-second test to help them make informed decisions about dry eye disease, and the
ASCRS OSD Algorithm deemed osmolarity an “essential” preoperative diagnostic test for
cataract and refractive surgeries. 1 It will remain a flagship device in the Trukera Medical
portfolio.
“Corneal health is an exciting focus for us because precise, predictive and practical
corneal evaluation can inform treatment in all aspects of ocular health,” explained
James V. Mazzo, Executive Chairman of the Board at Trukera Medical. “Customers have
expanded the use of osmolarity testing from aiding in the diagnosis and management of
corneal disease to ensuring risk factors are identified for minimizing refractive surprises
after surgery. As Trukera, we’re looking forward to helping improve patients’ lives even
further by advancing doctors’ capabilities around corneal health.”
The first new product under the Trukera Medical brand will be announced later this
month and launched at the upcoming World Cornea Congress and American Academy of
Ophthalmology. To learn more and get the latest news, visit www.TearLab.com.
1. Starr CE, Gupta PK, Farid M, et al. An algorithm for the preoperative diagnosis and treatment of ocular surface
disorders. J Cataract Refract Surg. 2019 May;45(5):669-684. doi: 10.1016/j.jcrs.2019.03.023.
About Trukera Medical
Trukera Medical is a global leader in developing and marketing comprehensive corneal
health technologies. The company introduced tear osmolarity testing to eye care with
its flagship device, the TearLab Osmolarity System, which has been used over 24 million
times worldwide. Trukera’s expanding portfolio continues to focus on improving corneal
health, both as a primary goal and in preparation for surgery. Get more details and new
product announcements at www.TearLab.com.
